Hui Hui Li

US Patent:

6380189, Apr 30, 2002

Filed:

Feb 11, 2000

Appl. No.:

09/502038

Inventors:

Norman Abood - Morton Grove IL
Daniel L. Flynn - Mundelein IL
Daniel P. Becker - Glenview IL
Brian M. Bax - St. Lcharles IL
Hui Li - Skokie IL
Roger A. Nosal - Buffalo Grove IL
Lori A. Schretzman - Gurnee IL
Clara I. Villamil - Glenview IL

Assignee:

G.D. Searle Co. - Chicago IL

International Classification:

A61K 31536

US Classification:

5142305, 544 92

Abstract:

A class of compounds for the treatment of viral infections. Compounds of particular interest are defined by Formula I wherein R-R are as defined herein, or a pharmaceutically-acceptable salt thereof.

US Patent:

6638952, Oct 28, 2003

Filed:

Dec 23, 1999

Appl. No.:

09/254530

Inventors:

Hui Li - Vernon Hills IL
Daniel P. Becker - Glenview IL
Clara I. Villamil - Glenview IL
Terri L. Boehm - Ballwin MO
Daniel P. Getman - Chesterfield MO
Joseph J. McDonald - Ballwin MO
Gary A. DeCrescenzo - St. Charles MO

Assignee:

Pharmacia Corporation - Skokie IL

International Classification:

A61K 31445

US Classification:

514330, 546221

Abstract:

An aromatic sulfonyl alpha-cycloamino hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated aromatic sulfonyl alpha-cycloamino hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.

US Patent:

6683077, Jan 27, 2004

Filed:

Jan 4, 2002

Appl. No.:

10/035433

Inventors:

Norman Abood - Morton Grove IL
Daniel L. Flynn - Mundelein IL
Daniel P. Becker - Glenview IL
Brian M. Bax - Irvine CA
Hui Li - Vernon Hills IL
Roger A. Nosal - Buffalo Grove IL
Lori A. Schretzman - Gurnee IL
Clara I. Villamil - Glenview IL

Assignee:

G.D. Searle Co. - St. Louis MO

International Classification:

A61K 31535

US Classification:

5142305, 544 92

Abstract:

A class of compounds for the treatment of viral infections. Compounds of particular interest are defined by Formula I wherein R-R are as defined herein, or a pharmaceutically-acceptable salt thereof.

US Patent:

6750233, Jun 15, 2004

Filed:

Sep 17, 2001

Appl. No.:

09/954451

Inventors:

Thomas E. Barta - Evanston IL
Daniel P. Becker - Glenview IL
Louis J. Bedell - Mt. Prospect IL
Terri L. Boehm - Ballwin MO
Jeffery N. Carroll - Collinsville IL
Gary A. DeCrescenzo - St. Charles MO
Yvette M. Fobian - Labadie MO
John N. Freskos - Clayton MO
Daniel P. Getman - Chesterfield MO
Joseph J. McDonald - Ballwin MO
Susan L. Hockerman - Chicago IL
Susan C. Howard - Fenton MO
Steve A. Kolodziej - Ballwin MO
Hui Li - Vernon Hills IL
Deborah A. Mischke - Defiance MO
Joseph G. Rico - Ballwin MO
Nathan W. Stehle - Ballwin MO
Michael B. Tollefson - OFallon MO
William F. Vernier - St. Louis MO
Clara I. Villamil - Glenview IL

Assignee:

Pharmacia Corporation - St. Louis MI

International Classification:

A61K 31382

US Classification:

514336, 514252, 514342, 514383, 514432, 544374, 5462801, 5482658, 549 28

Abstract:

A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.

US Patent:

6763353, Jul 13, 2004

Filed:

Oct 31, 2001

Appl. No.:

09/984975

Inventors:

Hui Li - Union City CA
Shelly Xiaolei Qian - Cupertino CA

Assignee:

Vitria Technology, Inc. - Sunnyvale CA

International Classification:

G06F 1730

US Classification:

707 4, 707 2, 707 3, 707 5, 705 1, 705 7, 709310, 718101

Abstract:

A method for monitoring a business process model in which at least one business process object transitions between states. A query having at least one state for the business process object and at least one time-based condition is defined. The query is applied to the business process objects that have changed since a last query application step as a result of execution of the business process model. Events are published when the results of the query are different from previous results of the query. The time based conditions can include conditions compared to actual time and can aggregated values of attributes of plural business process objects and current time.

US Patent:

7060827, Jun 13, 2006

Filed:

Jun 1, 2004

Appl. No.:

10/858343

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07D 239/02

US Classification:

544323, 544324, 544320

Abstract:

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

US Patent:

7115658, Oct 3, 2006

Filed:

May 9, 2003

Appl. No.:

10/434702

Inventors:

Allen J. Borchardt - San Diego CA, US
Peter Scott Dragovich - San Diego CA, US
Javier Gonzalez - Oceanside CA, US
Tanya Michelle Jewell - Encinitas CA, US
Hui Li - Carlsbad CA, US
Maria Angelica Linton - San Diego CA, US
John Howard Tatlock - San Diego CA, US
Ru Zhou - Carlsbad CA, US
Thomas Jay Prins - Cardiff CA, US
Melwyn A. Abreo - Jamul CA, US

Assignee:

Agouron Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/351

US Classification:

514460, 514459, 514336, 514365, 514452, 514364, 514378, 514405, 514326, 5142315, 514422, 51425931, 514384, 514397, 5142621, 514456, 5142581, 514382, 51425505, 514369, 514274, 514340, 514363, 514375, 5142541

Abstract:

Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.

US Patent:

7122542, Oct 17, 2006

Filed:

Jul 30, 2004

Appl. No.:

10/903870

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Hui Li - Millbrae CA, US
Somasekhar Bhamidipati - Foster City CA, US
David Carroll - San Francisco CA, US
Catherine Sylvain - Burligame CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 19/02
A61K 31/535
C07D 268/36

US Classification:

5142305, 544105

Abstract:

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.